The renewal of my Practitioner Fellowship will continue to facilitate an expanding program of epidemiological and clinical research in viral hepatitis, with a primary focus on hepatitis C. New directions will include development of international clinical cohort and trials networks, particularly to characterise the natural history of early hepatitis C infection and evaluate hepatitis C therapuetic strategies for injecting drug users.
Hepatitis C Vaccines: Preclinical To Clinical Development
Funder
National Health and Medical Research Council
Funding Amount
$474,244.00
Summary
Hepatitis C is one of the most common notifiable infectious diseases in Australia with 200,000 infected individuals and 10,000 new infections each year. Treatments currently available for hepatitis C are effective but also associated with significant side effects and expensive. The economic and health burden of hepatitis C infection and the high costs of emerging antiviral therapies makes the development of an effective vaccine for HCV imperative. This project aims to develop a vaccine for the p ....Hepatitis C is one of the most common notifiable infectious diseases in Australia with 200,000 infected individuals and 10,000 new infections each year. Treatments currently available for hepatitis C are effective but also associated with significant side effects and expensive. The economic and health burden of hepatitis C infection and the high costs of emerging antiviral therapies makes the development of an effective vaccine for HCV imperative. This project aims to develop a vaccine for the prevention of hepatitis C infection.Read moreRead less
Implementation Of Highly Effective Therapy For Hepatitis C
Funder
National Health and Medical Research Council
Funding Amount
$569,219.00
Summary
Hepatitis C is a major public health issue in Australia, and globally, with escalating liver disease burden. Highly effective interferon-free HCV regimens will be available from 2016 and have the potential to provide one of the greatest advances in clinical medicine in recent decades. Development of implementation strategies for new HCV therapies, particularly for highly marginalised populations including people who inject drugs and prisoners, is crucial to provide broad public health impact.
Implementing And Enhancing Evidence-based Research And Practice In Hepatology
Funder
National Health and Medical Research Council
Funding Amount
$569,219.00
Summary
The overall aim of this proposal is to tackle unmet challenges in liver disease research. This will be achieved through (a) Population level programs to deliver new treatments for patients with hepatitis C; (b) Developing integrated care models to treat hepatitis B; (c) Developing population-level programs for liver cancer control; and (d) Identification of patients at risk of severe liver disease through understanding the genetic basis of disease progression.
Determinants Of The Outcomes From Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$585,269.00
Summary
This Fellowship will allow Professor Lloyd to continue clinical and laboratory research in two areas: firstly, in relation to prevention of transmission of hepatitis C infection, and scale up of antiviral treatments, particularly amongst prisoners. Secondly, in studies investigating the biological basis of chronic fatigue states following acute infection or cancer treatment, and also in development of effective treatment for chronic fatigue states.
Determinants Of The Outcomes From Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$532,630.00
Summary
Professor Lloyd will continue studies of the factors which lead to varied clinical outcomes from common infectious diseases. The outcomes include chronic or persistent illness, rather than prompt recovery. The factors being studied include aspects of the microbes causing the infection; and aspects of the individual suffering from infection, including genetic make-up, immune defences, and treatment responses. The infections studied include common "flu-like" illnesses, as well as hepatitis C.
This Practitioner Fellowship will support studies that will contribute directly to the efforts to eliminate HCV infection from Australia. The research program aims to reduce transmission of HCV infection by evaluating the best models of care for i) engaging and treating high risk individuals with HCV infection, including people who inject drugs and prisoners, ii) preventing reinfection with HCV, and iii) re-treatment of individuals who fail treatment due to drug resistance.